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ABSTRACT
Introduction: Sepsis is a disease that occurs due to an adverse immune response to infection by 
bacteria, viruses and fungi and is the leading pathway to death by infection. The hallmarks for 
maladapted immune reactions in severe sepsis, which contribute to multiple organ failure and death, 
are bookended by the exacerbated activation of the complement system to protracted T-cell dysfunc-
tion states orchestrated by immune checkpoint control. Despite major advances in our understanding 
of the condition, there remains to be either a definitive test or an effective therapeutic intervention.
Areas covered: The authors consider a combinational drug therapy approach using new biologics, and 
mathematical modeling for predicting patient responses, in targeting innate and adaptive immune 
mediators underlying sepsis. Special consideration is given for emerging complement and immune 
checkpoint inhibitors that may be repurposed for sepsis treatment.
Expert opinion: In order to overcome the challenges inherent to finding new therapies for the complex 
dysregulated host response to infection that drives sepsis, it is necessary to move away from mono-
therapy and promote precision for personalized combinatory therapies. Notably, combinatory therapy 
should be guided by predictive systems models of the immune-metabolic characteristics of an indivi-
dual’s disease progression.
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1. Introduction
The term sepsis, derived from the ancient Greek meaning to 
‘make rotten’ and referring to the decomposition of organic 
material, was first coined by Hippocrates [1,2]. Nowadays, 
sepsis is viewed as a complex multi-stage and multifactorial 
condition defined as a life-threatening organ dysfunction 
caused by a dysregulated host response to infection [3]. 
Sepsis leads to shock, multiple organ failure, and death, espe-
cially if not recognized early and treated promptly.
In sepsis, the immune response initiated by an infecting patho-
gen fails to revert to baseline homeostasis, consequently leading 
to a pathological condition characterized by sustained excessive 
inflammation and T-cell immune suppression. Despite the 
advances in diagnostic procedures and therapeutics, sepsis 
remains the leading cause of death in surgical and general inten-
sive care units. In 2017 the World health Organization identified 
sepsis as a global health priority [4]. A precise estimate of the 
epidemiology burden of sepsis is difficult to ascertain; some pub-
lications estimate that every year worldwide more than 30 million 
people are affected, potentially leading to 6 million deaths, while 
other reports claim that the annual number of cases is closer to 
50 million and that 19.7% of deaths worldwide are sepsis related 
(11 million per annum) [5,6]. Moreover, patients who survive sepsis 
often suffer from post-sepsis symptoms, including long-term func-
tional disabilities and cognitive impairment with substantial health 
care, economic and social repercussions [4,7]. Accordingly, sepsis 
is a significant health issue with high mortality and morbidity, 
causing a major impact on human life and resource utilization [4].
The identification and treatment of sepsis is an ongoing 
challenge for medical professionals. Traditionally, sepsis treat-
ment relies on the management of bacterial infections through 
the use of antibiotic therapy directed against the infecting organ-
ism [8]. In the majority of cases the causative agent or initial 
provoker is not identified, may not be bacterial or may be poly- 
microbial with undetectable loads. As with all infections it is the 
ensuing maladapted immune pathogenic pathways of the host 
that causes severity of disease. For this reason, a plethora of 
studies have been carried out focusing on the modulation of 
the immune system response to infection, given that, it is this 
response that ultimately leads to organ dysfunction [4,9,10]. The 
complement system is a key trigger component of innate immu-
nity that provides an initial critical orchestration of the multi-
faceted defense against infection. A cardinal feature of the 
systemic overactive inflammatory response observed in sepsis 
is complement activation. There are three complement path-
ways – alternative (AP), classical (CP), and lectin (LP) – evolved 
to activate different biological functions, leading to the produc-
tion of several anaphylatoxins (C3a, C5a) and other active pro-
ducts that impart both protective and harmful effects in sepsis 
[11]. Furthermore, complement receptors govern a link to adap-
tive immune cells where their expression on these cells provides 
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important signals for B cell maturation and induction of 
T-effector cell functions.
Over the last 30 years, a wide range of sepsis clinical trials 
targeting immunity have been undertaken, following promis-
ing results reported in animal models [4]. However, these 
results failed to translate in a clinical setting which has raised 
many unanswered questions, including the validity of animal 
models, consideration of patient heterogeneity, and interven-
tions that are applied too late for reversing the disease course 
or fail to account for the multifactorial nature based on 
a single therapeutic target [2,4,12–15].
Currently, high acuity physiologic parameters are used to 
stratify an at risk population, assuming the resultant mortality 
will be high, and fail to take into account the heterogeneity 
within the groups, including the patients molecular, cellular 
and genetic traits, comorbidities, and preferences for care 
[2,12]. The consequences of this practice are two-fold, first 
the inclusion of patients that will not benefit from treatment 
(the very frail) and second an absolute requirement for 
a much larger sample size to compensate for patient 
heterogeneity.
We contend that there is an undeniable need for 
a completely new approach to sepsis research and medical 
treatment. New systems biology methodologies are begin-
ning to help better delineate disease pathways and patient 
stratification; however, a systems medicine approach 
enabling precision diagnostics and treatment is lagging 
behind.
Here, we will not cover in detail the many emerging sys-
tems biology investigations but will highlight key areas with 
a particular focus given to sepsis target validation for biologic 
therapeutics with emphasis on the possibility of repurposing 
drugs used for complement and immune checkpoint targeted 
therapies. We first discuss the complement system followed by 
immune checkpoint inhibition and highlight the use of host- 
directed pathway modeling for precision combinatory 
therapy.
2. Complement system
The complement system is one of the first line responders to 
infection orchestrating defense and host protection pathways 
from the innate to the adaptive immune systems [16–18]. 
Although it is primarily perceived as a host defense mechan-
ism, it plays a much broader functions in immune surveillance 
and homeostasis [16,18,19]. However, aberrant activation of 
the complement system can cause tissue damage and organ 
failure [20,21]. The three interconnected activation pathways 
(CP, LP, and AP) are triggered immediately after encountering 
a pathogen by pattern recognition molecules (PRMs). These 
three pathways all converge on the activation of C3 by C3 
convertases, leading to the release of the C3 split products, 
C3a and C3b [22]. C3b participates in the formation of C5 
convertase, which activates C5 to C5a and C5b, the latter 
initiating formation of the membrane attack complex (MAC). 
Both C3a and C5a are anaphylatoxins that critically promote 
acute inflammation, including recruiting and activating leuko-
cytes, endothelial cells and platelets, as well as inducing plate-
let aggregation, smooth muscle contraction, capillary leakage 
and, potentially, anaphylactic shock [23–25]. The amplitude 
and duration of complement activation impacts downstream 
immune intensity at multiple levels.
2.1. Pattern recognition molecules (PRMs)
For detection of tissue damage or microbial infection, immune 
cells express a set of receptors known as PRMs, which recognize 
pathogen-associated molecular patterns (PAMPs) expressed by 
invading and innocuous microorganisms alike [26,27].
PRMs can be divided based on their location into cell 
associated and fluid phase molecules [28]. The latter function 
as the ancestors of antibodies and have a variety of roles, 
including complement activation, opsonization, agglutination, 
neutralization and regulation of inflammation [29–32]. Soluble 
PRMs include lectins of the ficolin, collectin and pentraxin 
(PTX) families and are expressed by different cell types includ-
ing myeloid, epithelial and endothelial cells [28,33–36].
2.2. Lectins and C1q
The members of the lectin family have two common structural 
characteristics, a collagen-like extended triple helix structure 
coupled to a compact recognition structure [34]. The latter 
defines the complement proteins as C-type lectins (Mannose 
Binding Lectin (MBL), Collectin-10 (CL-10), and Collectin-11 (CL- 
11)) that express a carbohydrate recognition domain (CRD) or 
ficolins (ficolin-1, ficolin-2, and ficolin-3) that have a C-terminal 
fibrinogen-like domain. The effector functions of collectins and 
ficolins are mediated via a set of proteases (MASP-1, MASP-2, and 
MASP-3) [37]. All three ficolins are able to forming complexes 
with MASPs to generate LP-activating complexes, though with 
varying degrees of efficiency [34].
2.3. Pentraxins
Pentraxins are a superfamily of phylogenetically conserved 
proteins divided into short and long pentraxins. The first 
Article highlights
● Sepsis is as a life-threatening complex multi-stage and multifactorial 
condition caused by a ‘dysregulated’ host response to infection.
● Diagnostic procedures and therapeutics based on a single biomarker 
or monotherapy have repeatedly been met with failure.
● Emerging potent biologic drugs targeting the complement system, 
cytokines and immune-check-point inhibition provide renewed 
opportunity, using a drug combination therapy approach, for target-
ing host pathways to curatively adjust the response to infection in 
sepsis.
● Understanding perturbation in homeostasis set-points and the 
dynamics of an adverse host response to infection is urgently 
needed.
● Combination therapy should consider a stratified approach targeting 
patient-specific maladapted innate and adaptive immune response 
pathways.
● Mathematical models for describing the first order effects in the 
resulting immune dynamics will be required to guide precision 
medicine and identify the ‘right’ patient for combinatory therapeutic 
intervention.
This box summarizes key points contained in the article.
2 P. R. S. RODRIGUES ET AL.
group includes C-reactive protein (CRP; a widely measured 
nonspecific inflammatory biomarker) and serum amyloid 
P (SAP), while PTX3, PTX4, neuronal pentraxin 1 (NP1) and 
NP2 belong to the latter group [27,33]. PTXs interact with 
complement activating PRMs and regulatory molecules.
CRP was the first PRM identified, as an antibody-like mole-
cule recognizing the C-type polysaccharide of pneumococcus, 
in the 1930s32. Subsequently SAP was identified through 
homology to CRP (amino acid sequence identity of 51%) 
[38]. Both CRP and SAP are major acute-phase reactants in 
humans, with low basal levels that increase markedly during 
the acute phase response [33]. For these reasons CRP has been 
extensively used clinically for over half a century as 
a nonspeci!c systemic marker of infection, in"ammation, and 
tissue damage [33].
Regarding long pentraxins, PTX3 is the most well studied 
and has served as a tool to study humoral innate immunity [32]. 
PTX3 has complex roles in pathophysiology that range from 
essential homeostatic functions, to defense against infectious 
agents, tissue repair and regulation of carcinogenesis [39,40]. 
Serum PTX3 levels have been associated with sepsis severity 
and mortality [41–43]. PTX3 can be released by a several cell 
types, including neutrophils and activated endothelial cells [44]. 
It recognizes and binds pathogens, leading to the activation 
and modulation of the complement system [45,46].
2.4. C1q
C1q has a similar structure and function to collectins; it com-
prises a collagen-like stalk or six intertwining chains that end 
in six globular heads that are the antibody (and other ligand) 
recognition domains. There are numerous receptors for C1q 
on a variety of cell types, suggesting direct roles in opsoniza-
tion and other processes, but for complement activation, C1q 
must bind its effector molecules C1r and C1s to form the C1 
complex. The classical and lectin pathways respectively are 
activated when C1q and MBL/ficolins bind to an activating 
structure. C1q also has important roles in maintaining immune 
tolerance via labeling and facilitating clearance of apoptotic 
cells, in phagocytosis of bacteria, and in neutralization of 
viruses. Deficiency of C1q is associated with autoimmune dis-
ease and increased susceptibility to infections [21].
2.5. Anaphylatoxins
The two anaphylatoxins generated through complement acti-
vation (C3a and C5a) interact with their receptors expressed 
on various cells, thereby inducing changes characteristic of an 
acute inflammatory response and are further suspected to act 
in the intracellular space to shape T cell fates. C5a is a potent 
agonist of myeloid cells which express high levels of C5aR. 
Research over the past three decades has shown that C5a has 
an important role in acute inflammatory diseases and in sepsis 
in particular [47]. There is now a much more in-depth under-
standing of the molecular and cellular mechanisms involved in 
C5a-induced harmful effects in sepsis. C3a interacts with C3a 
receptors (C3aR) on several cell types, thus promoting degra-
nulation of basophils and mast cells, which causes edema and 
constriction of smooth muscle, especially in the gut and upper 
airways of the lungs [48]. Intracellularly, activated C3 may act 
as a ‘chaperone’ that guides the processing of an apoptotic 
cargo, likely modulating T cell responses to self-antigens dis-
played on dying cells [49]. Further, while little is known about 
the intracellularly complement system links between cellular 
metabolism during immune cell homeostasis and effector 
functions have been discussed [50].
2.6. Complement regulators in sepsis
The importance of complement system regulation is under-
scored by the large number of molecular players identified 
(Table 1). Malfunctioning complement regulation and defi-
ciency of particular regulators acting early in the cascade can 
result in both host cell damage and accumulation of immu-
nological debris. Conversely, tumor cells and pathogenic 
microorganisms can over-express or hijack host complement 
regulators and mimic the protective properties of the host 
organism, thus escaping complement surveillance, resulting 
in unrestricted growth and infections. Accordingly, in sepsis, 
complement can be both an asset and a liability. It acts as an 
asset in the defense against pathogens, by inducing opsoniza-
tion and direct killing by the MAC, and by triggering inflam-
matory responses through C3a and C5a and its receptor [23]. 
While these activation products are not necessarily the initiat-
ing factors that lead to harmful effects, they are responsible 
for promoting and perpetuating inflammatory reactions [24]. 
For example, signaling of C5a receptors (C5aR) on phagocytes 
(neutrophils, macrophages) is as an important contributor to 
multiorgan dysfunction, apoptosis, deterioration of the coagu-
lation/!brinolytic system and contractile dysfunction of cardi-
omyocytes in sepsis [51–53]. Also notable, is the role of C3 
activation pathways in promoting the development of mye-
loid derived suppressor cells (MDSCs) that are elevated in 
sepsis and contribute to neutrophil and T cell suppression 
[54,55].
Table 1. Complement regulators and receptors.
Regulator (alternative name) Acts on
Soluble regulators
Factor H Alternative pathway
FHL1 Alternative pathway
Properdin Alternative pathway
Carboxypeptidase N (anaphylatoxin 
inactivator)
Classical pathway and lectin 
pathway
C4BP Classical pathway and lectin 
pathway
C1INH Classical pathway and lectin 
pathway
CFHR1 Alternative pathway
Clusterin (SP-40,40; apolipoprotein J) Terminal pathway
Vitronectin (S-protein) Terminal pathway
Surface bound regulators
CR1 (CD35) C3 convertase
CRIg (VSIG4) C3 convertase
CD46 (MCP) C3 convertase
CD55 (DAF) C3 convertase
CD59 MAC assembly
Receptors for complement effector proteins
C3aR C3a
C5aR (CD88) C5a
C5L2 C5a
C1qR (CD93) C1q
SIGNR1 (CD209) Classical pathway
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Fluid-phase complement regulators target both host and 
non-host surfaces and act at multiple levels of the comple-
ment cascade [56]. For instance, C1 inhibitor (C1INH) inhibits 
the CP and LP of the complement system by neutralization of 
C1r and C1s or MASP activities and is the main inhibitor of the 
contact phase system by inhibition of factor FXIIa, kallikrein, 
and FXIa [57].Due to the anti-inflammatory properties of 
C1INH, it has been considered as a potential therapy to treat 
inflammatory diseases such as sepsis [58]. Properdin is the 
only known positive regulator of complement activation. 
A serum protein, it increases the production of complement 
activation products in the alternative pathway by binding and 
stabilizing the convertase complex, C3bBb [59]. In sepsis 
patients, properdin concentrations at ICU admission were 
decreased in non-survivors of sepsis, suggesting that 
Properdin may be used as a predictive marker of outcome in 
the initial stage of sepsis. Factor H is a fluid phase negative 
regulator of amplification through the alternative path-
way [56].
3. Targeting the complement pathways in sepsis
In humans complement plays a crucial role for the initiation 
and progression of sepsis and sepsis associated multiple organ 
dysfunction syndrome (MODS). Hence, we consider targeting 
complement proteins or molecules involved in complement 
activation as representing an early innate-immune targeting 
approach. As previously mentioned, the C5a/C5aR axis is 
strongly correlated with disease severity and mortality in sep-
sis. Keshari et al. tested RA101295, a 2-kDa macrocyclic pep-
tide inhibitor of C5 cleavage, in an in vivo baboon model of 
Escherichia coli (E. coli) sepsis and concluded that treatment 
was associated with significantly improved survival, reduced 
inflammation and coagulopathy, as well as significantly 
improved organ function compared to controls, suggesting 
improvement of sepsis-induced MODS [60]. Notably, this 
baboon model promisingly shows the potential impact of 
complement blockade up to 36 hours after initiation of sepsis. 
Whether this holds in humans remains open and may only 
translate for bacterial infections acquired in the ICU.
In another baboon sepsis model study, a different group 
assessed the effect of systemic blockade of C3 using comp-
statin. They showed reduced complement activation, sepsis- 
induced coagulopathy and preserved anti-coagulatory fea-
tures of the endothelium. C3 inhibition also improved hemo-
dynamics and heart function and reduced biochemical 
damage markers of the kidney and liver, indicating protective 
effects in sepsis-induced MODS [52].
With regard to applicability in the clinical setting, research 
has shown that the inhibition of C5 activation by the inhibi-
tory antibody eculizumab [61], might be compromised in the 
context of sepsis due to the overwhelming activation of the 
system and the interwoven nature of the complement cascade 
[9,10,62]. Furthermore, other serine proteases such as elastase, 
trypsin or thrombin, increased in tissues in sepsis, can in 
a redundant manner cleave and activate C5 and produce 
C5a [16,24,53]. For these reasons, a C5a-blocking rather than 
C5 blocking approach has been favored as a targeted 
approach in sepsis [63,64]. Blocking C5a in experimental 
models of sepsis has been shown to produce positive results 
[47]. Indeed, earlier studies in the 1980s, using rabbit polyclo-
nal antibodies to inhibit C5a in a primate model of sepsis 
induced by infusion of live E. coli, indicated that C5a blockade 
could significantly attenuate acute sepsis induced lung injury 
and failure [65,66]. Likewise, the blockade of C5a with anti-
bodies in rats and pigs was shown to be highly effective in 
diminishing severity of sepsis and improving outcome [67–72]. 
C5a/C5aR targeted drugs such as IFX-1, Avacopan and 
ALXN1007, have shown potential for therapy of a wide panel 
of diseases, including sepsis [73,74].
Plasma-derived C1INH was developed for treatment of her-
editary angioedema, caused by a partial deficiency of C1INH. 
Administration of C1INH in septic baboons had a beneficial 
effect on sepsis progression, via inhibiting complement activa-
tion and reducing cytokine release [58].
3.1. Clinical trials
Over the years, several complement interventions have been 
tested in preclinical models of sepsis in nonhuman primates 
with positive results as noted above [60,75]. However, few 
have entered human clinical trials to date and, like many 
other monotherapy approaches in sepsis, none have to date 
shown sucess [76,77]. While the precise reasons for failure are 
unclear, these interventional trials failed to account for the 
dynamic behavior of the pathway and the relative levels of 
components. For example, an important consequence of 
complement activation, as with all excitable systems, is 
a period of refractoriness post-activation and this period 
therefore may represent an unregulated state of the system. 
It is also notable that complement depletion often occurs 
during sepsis [11,70,71,78]. In this connection, a prospective 
observational study revealed that depletion of C3 is asso-
ciated with poor prognosis in severe abdominal sepsis invol-
ving dysregulated coagulation and increased susceptibility to 
infections [11].
In regard to interventional trials, there have been two 
attempted so far. One study utilized C1INH in a double-blind 
randomized placebo-controlled trial in trauma patients with 
a femur fracture (CAESAR; NCT01275976); however, this was 
terminated early due to challenges in recruitment [77]. 
The second trial used a monoclonal antibody against C5a, to 
prevent septic organ dysfunction (CIENS; NCT02246595), the 
outcome of this study is yet to be made available. It should be 
noted that there remain concerns for potential side effects of 
C5a blockade in compromising its neuroprotective effects 
[79,80]. Notwithstanding these complications there remains 
an abundance of evidence that complement is activated or 
dysregulated in the human disease and is therefore perhaps 
the most compelling reason to maintain exploring comple-
ment blockade.
Critically, sepsis is multifactorial disease involving many 
immune and metabolic pathways. Accordingly, just targeting 
one pathway may not in itself be sufficient for an intervention 
therapy. The complement pathway represents an upstream 
early acute response pathway and it could be that, further 
downstream, other immune homeostasis pathways should 
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also be taken into consideration. Key downstream immune 
modulatory therapeutics could involve inhibitors of inflamma-
tory cytokines, such as anti-TNF, anti-IL1, however in large 
multicentre randomized control trials these approaches have 
also failed as monotherapies. Another and perhaps more cen-
tral homeostatic link between the innate and adaptive arms of 
the immune system is via immune-check point control; this 
describes the co-stimulatory and co-inhibitory pathways of 
communication between myeloid antigen presenting cells 
and adaptive immune T-cells. In this connection, it has 
recently been demonstrated that opsonization of apoptotic 
cells by C1q induces an increased expression of the immune 
checkpoint regulators Programmed Death-Ligand 1 (PD-L1) 
and Programmed death-ligand 2 (PD- L2), and reduced CD40 
expression at the surface of macrophages [81].
4. T cell dysfunction and immune checkpoint control 
in sepsis
4.1. Co-stimulatory and Co-inhibitory pathways
The innate and adaptive arms of the immune system physi-
cally communicate through bi-directional signaling via the 
immunological synapse. This exchange is tightly regulated by 
a large array of co-signaling molecules that can act as stimu-
lators and/or inhibitors [82]. These key regulators serve 
a central hub for regulating the state of immune reaction 
termed immune checkpoint control. The immune-check 
point controls are crucial for the activation and resolution of 
an immune response and have critical roles in the mainte-
nance of self-tolerance, preventing autoimmunity and protec-
tion from damage during infection. The response of the 
immune system in severe sepsis is characterized by 
a dysfunctional T-cell inhibitory state and prolongation of 
this state is thought to be a contributing factor for sepsis- 
induced mortality and morbidity [83–85]. In particular, and 
similar to many cancers, there is a dominance of co- 
inhibitory over activating receptors, expansion of suppressive 
cell types, immune cell depletion, T cell dysfunction, and 
induction of inhibitory ligands on both antigen presenting 
cells and tissue parenchymal cells [86].
T cell dysfunction ultimately culminates in apoptosis of the 
cell and is considered an altered differentiation state, often 
characterized by features such as loss of effector functions, 
continuous upregulation of several cell surface inhibitory 
receptors, downregulation of co-stimulatory receptors, 
reduced production of cytokines (IFN-#, IL-2, TNF-$), altered 
expression of key transcription factors, and metabolic 
derangements [87].
During normal immune activation response, inhibitory 
receptors are transiently expressed in functional T cells, how-
ever a continuously higher expression is a hallmark of T cell 
dysfunction [87]. There are well over 160 characterized co- 
inhibitory and co-stimulatory molecules reported to date. 
Notably, dysfunctional T cells are known to express a range 
of cell surface inhibitors (Table 2 and Table 3), and the higher 
the frequency of co-inhibitors expressed by T cells, the more 
severe the dysfunction [88].
Co-stimulatory and co-inhibitory pathways are now recog-
nized as the main component in modulating host response in 
acquired diseases ranging from cancer to infectious diseases 
[109]. While co-stimulation is indispensable for boosting and 
molding the initial response following signaling through the 
antigen receptor, inhibitory pathways are also essential for 
modulating the immune response by controlling autoreactiv-
ity and immunopathology [87,109,110].
One of the best characterized inhibitory pathway is 
mediated by PD-1 in response to binding PD-L1 and/or PD- 
L2 and helps elucidate some of the mechanisms by which 
inhibitory receptors may control T cell function: sequestering 
of target receptors or ligands and/or preventing the optimal 
formation of microclusters and lipid rafts; modulation of intra-
cellular mediators; induction of inhibitory genes [110,111]. 
However, co-stimulatory receptors also play crucial roles in 
T cell dysfunction. The loss of adaptor molecules can lead to 
the desensitization of co-stimulatory pathways thus serving as 
a mechanism of T cell dysfunction during infection.
4.2. Existing Immune checkpoint mediators implicated in 
sepsis
The immune system response in sepsis exhibits multiple states 
of immunosuppression that range from a variety of innate and 
adaptive processes. Notably, immune checkpoint co-inhibitors 
such as PD-1, PD-L1, CTLA-4 and BTLA display an upregulation 
on immune cells during sepsis and have been hypothesized to 
be among the key contributors causing sepsis-induced 
immune cell dysfunction [112].
The role of expression levels of these inhibitors in sepsis 
has been extensively researched both in pre-clinical models 
and clinical trials and is summarized in Tables 2 and 3. The 
PD-1/PD-L1 axis is the most well studied immune check-
point interaction in sepsis immunopathology and has been 
shown to be involved in intestinal and liver injury during 
sepsis. However, additional studies are required to reveal 
the exact role of PD-L1 in various organ injuries such as 
kidney, brain, lung, heart and others during sepsis 
[23,82,113–117].
A comprehensive and first systems biology analysis high-
lighting immune checkpoint co-stimulatory and co- 
inhibitory pathways described the clinical investigation of 
neonatal sepsis [118]. Here a systematic profiling of all 
known (>160) immune checkpoint regulators identified 41 
immune checkpoint regulators statistically altered in expres-
sion levels in blood-culture positive sepsis patients. Most 
notably, co-stimulatory molecules such as CD28, ICOS, 
CD40L, CD27, CD2 were significantly down-regulated in 
expression, while co-inhibitory genes such as PDL1, 
LGALS9, CD85A (LILRB3), CD85K (LILRB4) were significantly 
up-regulated in expression (Figure 1) (Table 3). It is worth 
noting that the LILRBs have been shown in mice not to be 
involved in hematopoiesis or normal development [119] and 
therefore represent ideal potential targets for treating sepsis 
in early life. It remains to be determined whether these 
molecules are involved in older populations or exclusive to 
neonatal sepsis.
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5. Targeting immune checkpoint pathways in sepsis
The levels of inhibitory immune checkpoint receptors such as 
PD-1, CTLA-4 and BTLA are increased during sepsis and are 
important contributors to sepsis-induced immune cell dysfunc-
tion [85,87,112]. The current view is that these inhibitory 
immune regulators hinder the immune responses needed to 
clear invading pathogens, or perhaps more importantly prevent 
the resolution phase of the immune response. However, it is 
possible that depleted T-cells may confer beneficial effects 
[120]. Thus, while therapies targeting immunosuppression are 
currently of great interest for the development of new sepsis 
treatments, caution in this enthusiasm should be noted until we 
understand better the precise role and function of T-cell subsets 
in sepsis. This is especially the case for tissue versus systemic 
T-cells. In principle, therapeutic applications of monoclonal 
antibodies of decoy receptors for blockade of co-inhibitory 
pathway antagonists would lead to the augmentation of T cell 
responses. This strategy could be employed to promote T cell 
immunity in sepsis, although in certain models tissue resident 
T-cells but not infiltrating T-cells appear less affected during 
sepsis which might impact the potentially beneficial role of 
anti-PD1/PD-L1 therapies [121,122]. While other models have 
highlighted the importance of homing to niche environments, 
in particular bone-marrow, for resolving T-cell homeostasis in 
response to systemic antigens, suggesting therapies should 
also account for relevant tissue localization[123].
Nevertheless, numerous pre-clinical studies using immu-
notherapeutic agents such as IL-7, anti-PD-1 have been able 
to reverse T cell dysfunction and improve survival [112]. 
Several pre-clinical studies have also shown that targeting 
PD-1 and PD-L1 during sepsis improves host resistance to 
infection [84]. Several experimental medicine studies have 
evaluated ex-vivo the potential therapeutic benefit of target-
ing the PD-1/PD-L1 axis in line with reversal of immunosup-
pression [9,124,125]. These investigations primarily tested anti- 
PD-L1 antibody upon treatment of isolated immune cells from 
septic patients indicating reduced T-cell apoptosis, increased 
T-cell IFN-# and IL-12 levels, elevated monocyte cytokine pro-
duction, as well as neutrophil and NK cell functions
6. Repurposing and combinatory therapies
In the last two decades several highly effective and specific 
complement therapies targeting different parts of the comple-
ment cascade (Figure 2) have been developed and introduced 
to the clinics, and many more are currently under develop-
ment (Table 4) [126,127]. Numerous complement-related 
pathologies share several common factors; hence, 
a complement-targeting drug approved for one disease may 
be repurposed for different ones. However, no complement 
intervention strategies have been implemented to effectively 
address the complex immune response observed during sep-
sis [9,10,128], and only a select few have been used in sepsis 
trials (Figure 2 orange crosses). Thus, it is highly important to 
look at the currently available drugs as a therapeutic ‘toolbox’ 
with a diverse panel of possible candidates for use in sepsis 
therapies. Besides complement activation products, such as 
anaphylatoxins, other molecules including CRP and PTX3 
play crucial roles in contributing to complement dysregulation 
in sepsis and trauma, thus profoundly in"uencing secondary 
outcomes. Therefore, it is possible that they have potential as 
both sepsis diagnostics and therapeutic targets.
Table 2. Pre-clinical studies showing alterations in expression of immune various checkpoints during sepsis.
Immune 
checkpoint
Alteration in 
expression Location Model Reference
PD-1 Increased Peritoneal macrophages CLP Huang et al., 2009 [89]
Splenic T and B cells and monocytes CLP Zhang et al., 2010 [90]
Kupffer cells CLP Hutchins et al., 2013 [91];  
Wang et al., 2016 [92]
CD4+ and CD8+ splenic T cells CLP Brahmamdam et al., 2010 [93];  
Chen et al., 2017 [94]
Candida fungal sepsis, and Two hit 
model (CLP + fungal sepsis)
Chang et al., 2013 [95]
Splenic CD4+, NKT and NK cells Two hit model (CLP + fungal sepsis) Shindo et al., 2017 [96]
No Change Splenic T cells Burn wound sepsis (Pseudomonas 
aeruginosa)
Patil et al., 2016 [112]
PD-L1 Increased Splenic B cells and monocytes CLP Zhang et al., 2010 [90]
Liver tissue CLP Zhu et al., 2013 [97]
Liver sinusoidal endothelial cells CLP Hutchins et al., 2013 [91]
Increased PD-L1 on macrophages, monocytes, T and 
Natural Killer T (NKT) cells and neutrophils
CLP Huang et al., 2014 [98]
intestinal epithelial cells CLP Wu et al., 2016 [99]
Splenic dendritic cells, macrophages and monocytes Burn wound sepsis (Pseudomonas 
aeruginosa)
Patil et al., 2016 [112]
CD4+ cells, NKT and Natural Killer (NK) cells Two hit model (CLP + fungal sepsis) Shindo et al., 2017 [96]
CTLA-4 Increased Splenic CD4+ and CD8 + T cells CLP Inoue et al., 2011 [100]
BTLA Increased Macrophages, monocytes, dendritic cells and 
neutrophils in peritoneum
CLP Shubin et al., 2012 [101]
Splenic CD4+ and CD8 + T cells CLP Chen et al., 2017 [94]
Peritoneal macrophages and dendritic cells; and in 
tissues- kidney, lung, liver and spleen
Two hit model (hemorrhage + CLP) Cheng et al., 2016 [102]
HVEM Increased Macrophages, monocytes, dendritic cells and 
neutrophils in peritoneum
CLP Shubin et al., 2012 [105]
2B4 Increased Splenic CD4+ and CD8 + T cells CLP Chen et al., 2017 [94]
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On the other hand, co-inhibitory receptor ligand pathways are 
central to tolerance mechanisms; their control of innate and 
adaptive immunity is an emerging and promising area of study 
for new sepsis therapies. Immune-checkpoint inhibitors have 
caused a seismic revolution in the treatment of cancer showing 
remarkable efficacy with 100% long-term remission. Cancer is an 
acquired disease, similar to infection, and perhaps an underlying 
chronic maladapted immune response in a cancer patient may 
have some of level of convergence with an acute sepsis condi-
tion in the context of functional T-cell exhaustion. Defining the 
role of immune checkpoint regulators in sepsis should provide 
important insights into the new avenues of immune intervention 
in disease. In oncology, there is clearly a consensus to move away 
from monotherapies to combination therapies of immune- 
checkpoint inhibitors. Here, we would propose a similar strategy 
should be considered for sepsis. However, unlike cancer, sepsis is 
a result of an acute extreme systemic immune response and 
therefore combinatory therapy for sepsis should accountant for 
moderating the overactive inflammatory state. In this scenario, 
we propose a combination of complement and immune- 
checkpoint inhibitors as a promising therapeutic modality.
7. Mathematical and predictive computational 
models
In this section, we do not discuss the many excellent systems 
biology studies in sepsis that can help in target discovery. 
Instead, as part of a computational systems approach for 
precision medicine, we believe that it is critical that early 
consideration is given to co-developing a formal framework 
that can guide patient stratification and optimization of ther-
apeutic modalities. Notably, the key mechanisms involved in 
the immune response to sepsis determine a complex system 
characterized by non-linear, time-dependent, interactions. 
Target validation and design of effective therapeutic interven-
tions require us to understand, and consequently control, the 
dynamics characterizing the onset and late stages of sepsis. 
The language of mathematics can describe, in an elegant and 
precise manner, the complex interactions underpinning the 
time course of the dynamics. This description, formalized in 
a mathematical model, and parameterized on an individual 
patient, allows testable predictions on the behavior of an 
individual’s response to a particular treatment.
Characteristically, in the immune system we can identify 
a duality in mechanisms of control, where key regulators 
orchestrate an immune response characterized by stimulatory 
and inhibitory effects acting in a reciprocally balancing fashion 
to ensure a measured response, limited in time. For example, 
in infection activation of the complement pathway triggers 
neutrophil activation (A) which leads to an amplification of the 
inflammatory response and T-cell activation (I) but can also 
cause the expansion of a subset of myeloid derived suppressor 
cells (MDSCs) that are anti-inflammatory and suppress neutro-
phil activation. When we formalize this system, specifying 
a negative feedback loop between A (the activator or 
response) and I (the antagonist or counter-response), together 
with upstream production and clearance, we obtain a minimal 
model, depicted in Figure 3 and described by the following set 
of ordinary differential equations:
dA
dt à !  "A  #AI
dI
dt à $AI   %I
⇢
(1) 
where t is time, ! à !H health!I infection
⇢
, " à "H health"I infection
⇢
, with 
!I>!H and "I<"H,
i.e. we assume that neutrophil activation and half-life are 
increased in infection, compared to healthy baselines.
This simple model can describe a number of different 
states, depending on the parameter regime. Analysis of the 
equations reveals the existence of two steady states (unchan-
ging in time),
P :
A⇤P à %$
I⇤P à 1#
$!
%   "
   
⇢
and Q :
A⇤Q à !"
I⇤Q à 0
⇢
(2)
where the * notation indicates steady state values for the 
cell populations.
Additionally, we find a threshold  % à $!" , below which P is 
stable, and above which Q is stable. Figure 4, illustrates the 
concept of stability for steady states. Because of noise present 
in nature, unstable steady states cannot be observed: any 
perturbation is amplified over time driving the biological sys-
tem away from that state.
Therefore, we expect that – after an initial transient phase – 
the dynamics will always drive the system to a stable steady 
state. Crucially, an infection triggering the immune response 
determines a change in the parameter regimes (in this exam-
ple ! and "), ultimately shifting both the threshold  %, and the 
steady state values. Note, in fact, that the T cell population at 
P and the neutrophil population at Q attain values that will 
vary in health compared to infection.
From such models we can identify distinct parameter 
regimes, corresponding to possible transitions that can occur 
from health to disease (Figure 5). In this example the model 
predicts that an infection can trigger three possible outcomes, 
corresponding to three distinct regimes, with post-infection: 
increased T cells (%< $!H"H ), increased neutrophils (%>
$!I
"I
), or both 
increased neutrophils and T cells ( $!H"H <%<
$!I
"I
).
This is a powerful example of how mathematical modeling 
can rigorously describe complex non-linear systems of inter-
actions and obtain predictions which can be ultimately utilized 
to extract guidelines on possible interventions. For instance, in 
the above system we can envision a clinical intervention 
which aims at shifting the patient’s specific parameters toward 
the required steady state regime, i.e. the required level of 
activation and inhibition. In this particular example, this can 
be accomplished by acting on the T cell population, through 
the use of checkpoint inhibitors that alter their clearance %, or 
their recruitment by neutrophils$. Alternatively, we could 
intervene to modulate complement activation thereby altering 
neutrophil inflammatory response !, or their clearance ". 
Notably, the model predicts that alteringn # alone (checkpoint 
inhibition by T cells), will not shift the system to a different 
regime of stability, i.e. it will not change the qualitative asymp-
totic behavior of the system. Additionally, if a patient is in the 
regime %> $!I"I , altering # will not change the quantitative 
asymptotic behavior of the system altogether, because the 
system will always fall in steady state Q. This model can further 
be used to model combinatory treatment regimes. 
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Nevertheless, this exemplar model elegantly shows how multi-
ple combined therapies need to be considered and can be 
‘tuned’ (personalized) in terms of timing of treatment and 
combination of treatment for a given patient.
Generally, the immune response is a collection of mechanisms 
acting as dualities, where a process, cell type, or mechanism is 
accompanied by its own antagonist in a negative feedback loop. 
The resulting dynamics are non-trivial. The basic system of inter-
actions considered above illustrates the potential for acting on 
the tunability characteristic of such systems. Employing the rig-
orous language of mathematics to build a minimal description of 
the interactions, we can highlight the first order effects in the 
resulting dynamics and identify targets for intervention. This 
modeling approach prioritizes the retention of key interactions 
as identified by the current experimental evidence. It is, there-
fore, inherently subject to continuous refinement as a new 
understanding emerges from experimental investigation and 
model prediction.
8. Expert opinion
8.1. Final remarks
Sepsis is at the same time one of the best known yet most 
poorly understood medical diseases. It is a common and 
lethal condition, and even though outcomes have 
improved, mortality remains high. There is evidence in sep-
sis, that activation of the complement system results in 
excessive production of anaphylatoxins, which prompt 
a series of events leading to septic shock, multiorgan failure, 
and lethality. Activation of sepsis in non-human primate 
models has been shown to occur in a biphasic pattern, 
the initial phase mediated by the bacteria and the later 
phase mediated by an endogenous mechanism possibly 
involving PRMs [129]. Increase of complement activation 
during the first phase of sepsis may relate to bacterial 
opsonization and is thus bene!cial to the host defense 
response [52]. Conversely, complement activation during 
the second stage of sepsis via CRP, MBL or other PRMs 
could be a major contributor to tissue injury and death 
[69]. Whilst the complement system is the initial driver, 
immune checkpoint regulation is the ‘master switch’ in 
charge of the immune response in sepsis; development of 
a personalized therapeutic strategy capable of targeting 
patients suffering from a dysregulation of either of these 
two mechanisms in a timely fashion would likely lead to an 
improvement in the chances of survival.
In the past decades, over 100 randomized clinical trials 
have tested the hypothesis that immunomodulatory com-
pounds modulating the septic response to infection can 
improve survival of patients with sepsis [12,130]. Clinical trials 
blocking C3 during the development of sepsis-caused MODS 
are often considered with caution or disregarded because of 
perceived enhanced infection risk; however, recent studies in 
primates have revealed that long term inhibition of C3 is 
potentially safe [131]. Nevertheless, these trials are still on 
hold and require further consideration of the impact of sepsis 
in cognitive functions [9]. Regarding trials using immune 
checkpoint regulation, despite promising results in pre- 
clinical and ex-vivo clinical trials, only one clinical study has 
been performed for evaluating the dose safety of anti-PD-L1 in 
sepsis patients. The study has been completed but results 
have yet to be published (ClinicalTrial.gov# NCT02576457).
However, it is now acknowledged that acute preclinical 
sepsis models do not represent accurately the disease pro-
gression observed in sepsis patients. It is important to 
acknowledge that significant differences exist between the 
animals used for sepsis models and humans, not only in 
Figure 1. Checkpoint regulators on immune cells.[118]
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terms of physiology but also the response to septic insult 
[4]. Thus, preclinical studies on novel sepsis therapies 
should aspire to better reproduce what is observed in the 
clinics by incorporating aged animals with various co- 
morbidities and subject to various interventions (e.g. anti-
biotic therapy). Additionally, computer-simulated models of 
sepsis can help predict how some complement therapies 
currently used for other diseases would impact the prog-
nosis of sepsis patients.
We believe, sepsis therapeutics cannot target every dis-
ease status, it is important to individually evaluate the 
different immune stages, their relevance, and target them 
in a patient-speci!c manner. In particular, when designing 
therapeutic measures using complement strategies it is cru-
cial to accurately measure the levels of the target comple-
ment factor or activation product in order to determine the 
exact status of complement activation, before any interven-
tion can be carried out. This approach would allow a precise 
and timely intervention tailored to the progression of sepsis, 
for each individual patient, by inhibiting or supporting the 
complement system in a way that enables the immune 
system to counteract the negative effects of the hosts 
Figure 2. Simplified scheme of the complement system with presently exploited targets of complement-directed therapeutic intervention highlighting the 
approaches thought to be of interest in sepsis. C3(H2O), hydrolyzed C3; C1-INH, C1 inhibitor; C5L2, C5a receptor-like 2; CP, classical pathway; CR, complement 
receptor; FB, factor B; Fcn, ficolins; FD, factor D; FH, factor H; FP, factor P (properdin); GPCR, G protein–coupled receptor; LP, lectin pathway; MAC, membrane attack 
complex; MASP, mannose-binding lectin–associated protease; MBL, mannose-binding lectin.
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dysregulated immune response to infection. Furthermore, it 
is likely that combinations of several immunotherapeutic 
agents that target different pathways will hold signi!cant 
potential for sepsis therapy [112,132,133]. Due to the varia-
tion in individual immune responses to a septic insult, 
combinations of immunomodulatory agents offer better 
odds of success than standalone therapy with any individual 
agent. Moreover, individual therapies could be adapted over 
the course of sepsis based on the temporal changes in 
immune responses [112,134]. However, it is not yet known 
what would be the best way to characterize the extent of 
the immune response for each individual patient. Here, we 
propose that validated predictive mathematical models 
need to be co-developed alongside therapeutics. These 
models, similar to modeling pharmacodynamics of drugs, 
minimally capture the first order dynamics of the immune 
response and can be parameterized to an individual.
Lastly, the burdens faced by the survivors of sepsis include 
long-term physical and neurocognitive impairments [135]. 
Studies have shown that admission to hospital with sepsis is 
associated with new functional disabilities, long-term cogni-
tive decline and increased health-care use and it is possible 
Table 4. Targets of complement therapeutics and drugs currently under clinical trial [126]. Some drugs are being used in different trials, in those cases the phase 
represented corresponds to the most advanced.
Target Drug Conditions
Phase 
1
Phase 
2
Phase 
3
C1r/s; MASPs Berinert Hereditary angioedema and organ transplant ✓ ✓ ✓
Cinryze Neuromyelitis optica, Hereditary angioedema and organ 
transplant rejection
✓
Ruconest Hereditary angioedema ✓
C1s Sutimlimab Agglutinin Disease, Cold ✓ ✓ ✓
C3 AMY-101 Complement Mediated Diseases ✓
APL-2 Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy ✓ ✓ ✓
APL-9 Coronavirus ✓
C5 Cemdisiran Atypical Hemolytic Uremic Syndrome, Berger Disease, 
Paroxysmal Nocturnal Hemoglobinuria
✓ ✓
Crovalimab (SK59) Paroxysmal Nocturnal Hemoglobinuria ✓
Eculizumab Atypical Hemolytic Uremic Syndrome, organ transplant 
rejection
✓ ✓ ✓
Nomacopan Paroxysmal Nocturnal Hemoglobinuria ✓ ✓ ✓
Pozelimab Paroxysmal Nocturnal Hemoglobinuria ✓
Ravulizumab Paroxysmal Nocturnal Hemoglobinuria, Neuromyelitis Optica 
Spectrum Disorder
✓ ✓ ✓
Tesidolumab Paroxysmal Nocturnal Hemoglobinuria ✓ ✓
Zilucoplan Paroxysmal Nocturnal Hemoglobinuria, Myasthenia Gravis ✓ ✓
Zimura Idiopathic Polypoidal Choroidal Vasculopathy, Geographic 
Atrophy, Macular Degeneration
✓ ✓
ABP 959 (eculizumab 
biosimilar)
Paroxysmal Nocturnal Hemoglobinuria ✓ ✓
C5a IFX-1 Pyoderma Gangrenosum ✓ ✓
C5aR1 Avacopan ANCA-Associated Vasculitis, C3 Glomerulopathy ✓ ✓ ✓
CR1 (Functional domains of CR1 targeted to 
endothelium via lipid ‘tail’)
Mirococept Ischemia reperfusion injury in the kidney allograft ✓ ✓
Expression of soluble CD-59 AAVCAGsCD59 Dry Age-related Macular Degeneration ✓
Factor B IONIS-FB-LRX Geographic Atrophy, Age Related Macular Degeneration ✓ ✓
LNP023 C3 Glomerulopathy, Paroxysmal Nocturnal Hemoglobinuria ✓ ✓
Factor D Danicopan C3 Glomerulopathy, Paroxysmal Nocturnal Hemoglobinuria ✓ ✓
ACH-5228 Paroxysmal Nocturnal Hemoglobinuria ✓
MASP2 Narsoplimab Lupus Nephritis, C3 Glomerulopathy ✓ ✓ ✓
Figure 3. Example of duality mechanism in the immune system. Complement activation in Neutrophils (A) induces inflammation and activates T cells (I), but also 
activates inhibitory MDSCs that curtail further neutrophil activation. Additionally, we assume upstream production of neutrophils (this includes activation by 
complement) and clearance by apoptosis of both cell types. Annotated parameters indicate the rate of a given interaction, and are positive constants. The flat ended 
arrow indicates a negative interaction.
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that targeting multiple -mechanisms might aid in addressing 
the underlying trajectory of the persistent inflammation 
endured by sepsis survivors [7,135].
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